Lenvatinib: all 359 studies that test it
Page 1 of 4. Open to participants first (137), then studies with results posted, then the rest; newest registration first within each.
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingNCT07847359Phase 2
- Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingNCT07843901Phase 2
- Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingNCT07835893Phase 2
- PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingNCT07827807Phase 2
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Phase 2
- STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingNCT07754734Phase 2
- Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07691515Phase 3
- Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
- HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07685535Phase 2
- Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidineEnrolling by invitationNCT07683949Phase 1/2
- Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2
- Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaRecruitingNCT07571551Phase 2
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicable
- Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingNCT07495579Phase 2
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
- Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2
- A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
- Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2
- First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentNot yet recruitingNCT07297654Phase 2
- Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingNCT07256223Phase 2
- Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicable
- Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical CancerNot yet recruitingNCT07177716Phase 2/3
- Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TBNot yet recruitingNCT07160361Phase 4
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingNCT07149090Phase 1/2
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Phase 2
- Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell CarcinomaRecruitingNCT07097935Phase 1/2
- Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsRecruitingNCT07096609Phase 1/2
- Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)RecruitingNCT07092514Phase 2
- Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver ResectionNot yet recruitingNCT07077798Not applicable
- Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2
- Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Phase 2
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
- Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)Not yet recruitingNCT06919848Phase 2
- Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Phase 2
- An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with LenvatinibNot yet recruitingNCT06884982Phase 2
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingNCT06880523Phase 2
- Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)RecruitingNCT06860477Phase 2
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)RecruitingNCT06859684Phase 2
- HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
- TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular CarcinomaRecruitingNCT06740370Not applicable
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2
- Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2
- Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNot yet recruitingNCT06648525Phase 2
- TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
- Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1
- Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaNot yet recruitingNCT06463548Not applicable
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingNCT06420440Phase 2
- Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT06417606Phase 4
- FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingNCT06409637Phase 1/2
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
- HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2
- Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
- Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2
- Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingNCT06327269Early Phase 1
- Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2
- Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)RecruitingNCT06261125Phase 2
- Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06253598Phase 2
- Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2
- HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Not yet recruitingNCT06210334Phase 2
- Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsRecruitingNCT06208462Phase 2
- Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192797Phase 2
- Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192784Phase 2
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Phase 2
- The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2
- A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionNot yet recruitingNCT06089382Phase 3
- bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicable
- bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicable
- Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2
- Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2
- Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingNCT05823987Phase 2
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingNCT05774899Phase 1/2